Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
about
The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcomaInhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItInsulin-like growth factor system in cancer: novel targeted therapiesSimulation predicts IGFBP2-HIF1α interaction drives glioblastoma growthProline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells.Inhibition of the proteolytic activity of pregnancy-associated plasma protein-A by targeting substrate exosite binding.Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysisIGF-I activates caspases 3/7, 8 and 9 but does not induce cell death in colorectal cancer cellsThe insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.Polycystic liver diseases.Insulin-like growth factors and neoplasia.Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women.Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily.Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinomaExtracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth.Expression of nuclear insulin receptor substrate 1 in breast cancer.The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.The insulin-like growth factor-I receptor as a target for cancer therapy.Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta1 integrins.Prospects of RNA interference therapy for cancer.Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomasTargeting the insulin-like growth factor axis as a cancer therapy.Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor.IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Strategies for tumor-directed delivery of siRNA.Favorable outcome associated with an IGF-1 ligand signature in breast cancer.In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.Novel role for insulin as an autocrine growth factor for malignant brain tumour cells.
P2860
Q24304458-C7076541-B9EC-46CC-9D2D-EC23C5FF04F9Q24810622-DD29B563-03C9-47CF-AD49-8A0F32122A68Q26752780-DD4A1B5D-F4BA-429A-8235-69BE6858F1B5Q28081603-85636F41-E57F-43C9-B5B1-332002B1240EQ28546518-2FB30744-AC52-4FEC-A099-A6C5869CADC5Q31078386-8FE3DAC8-E589-4AAD-82A7-07D9B234A809Q33330587-F655CC51-CB77-4767-A821-FB3183AD0426Q33378824-A133F2C9-9638-43E5-A7BA-60BB9AA79B7EQ33449944-83AD73D8-57FF-44D7-9BBF-B923CA6C14D4Q33882569-4FCDB2E2-2193-49E3-A41A-8C0A566AA5E9Q33949172-F9117ED6-9AE7-440C-ADE8-55D944FBA85FQ34330521-ACAD5FCC-53B1-4C19-8E14-FA6E1C5B14FCQ35083425-6F85E713-54A3-4CFB-9E09-075A8C910921Q35221813-9699A5F3-82A1-48C2-A98E-8599286460E6Q35222052-0EBC9EF0-E7F6-4584-AC08-0BE88AAF7CF1Q35847939-7A1F1CB5-595F-4C8D-8097-AAF097E4CCB3Q35954427-7A2D438C-F996-4A96-8653-6D1927A8FBC8Q35964712-1367A153-8C91-4554-9257-BD733D918D50Q36185627-3CD3A25D-364D-4948-A7F5-09A0F880F5A7Q36219706-539B80CB-6709-445F-879F-4A79BAA3C35DQ36322254-0DE31C93-FC9C-4296-B651-FFEA42B62F86Q36337922-D5E965FA-0429-4005-BB1B-43B378FBC798Q36409237-E8540378-45ED-4E3A-8688-92FF9FA443C1Q36429684-DF6414F0-950F-4499-BAFE-B3C1921E0905Q36559639-1FFFAC4C-9DD7-4854-8DC3-3CAD73DDC92DQ36685345-3590E7B7-6BA4-407A-8FB3-A70F41FA1210Q36701142-24AA3DC2-3D26-4AB1-A2D2-D0B4CA7195C4Q36970632-E3B9D52C-3102-41B3-B473-C17D1BD5A2FDQ37060540-7B311E91-5C72-4804-BD18-1D07190343F5Q37271044-5DFFB758-B06E-4616-8699-797AD373E63DQ37397276-5262A762-7225-44E0-984C-65ACA8C0A074Q37588787-E406BE59-E999-45F6-9C27-28DAF57DF319Q37727180-D9EAC633-1132-4D45-92D8-44BC749D5CD0Q37840092-2C598056-328E-4A4C-A150-E0676AEDC79BQ38328093-ECFEC575-A445-4661-86D3-E1697AC8F8EEQ38850952-371A67AC-2486-496A-AEFE-09E59D8009DCQ39096931-473293B5-50DA-43A8-B0DA-14EA7271822BQ39147077-230D476E-1DA1-4B06-8DAC-9C7097F696F2Q39193890-D9BAB2C7-C056-4E38-82EB-246A968F094BQ40132300-0F5DCD8E-4E57-4639-B04E-05022D4A3E37
P2860
Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Growth factor receptors as the ...... like growth factor I receptor.
@ast
Growth factor receptors as the ...... like growth factor I receptor.
@en
type
label
Growth factor receptors as the ...... like growth factor I receptor.
@ast
Growth factor receptors as the ...... like growth factor I receptor.
@en
prefLabel
Growth factor receptors as the ...... like growth factor I receptor.
@ast
Growth factor receptors as the ...... like growth factor I receptor.
@en
P2860
P356
P1433
P1476
Growth factor receptors as the ...... like growth factor I receptor.
@en
P2093
Eva Surmacz
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206772
P407
P577
2003-09-01T00:00:00Z